Corcept Therapeutics (Corcept Therapeutics) Total Liabilities : $114.8 Mil (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Corcept Therapeutics Total Liabilities?

Corcept Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 was $114.8 Mil.

Corcept Therapeutics's quarterly Total Liabilities increased from Jun. 2023 ($103.01 Mil) to Sep. 2023 ($132.34 Mil) but then declined from Sep. 2023 ($132.34 Mil) to Dec. 2023 ($114.81 Mil).

Corcept Therapeutics's annual Total Liabilities increased from Dec. 2021 ($47.95 Mil) to Dec. 2022 ($81.59 Mil) and increased from Dec. 2022 ($81.59 Mil) to Dec. 2023 ($114.81 Mil).

Corcept Therapeutics Total Liabilities Historical Data

The historical data trend for Corcept Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corcept Therapeutics Total Liabilities Chart

Corcept Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

41.13

48.39

47.95

81.59

114.81

Corcept Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															81.59	88.26	103.01	132.34	114.81

Corcept Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Corcept Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	104.505	+	(0	+	10.307
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	114.8

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	621.517	-	506.705
	=	114.8

Corcept Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	104.505	+	(0	+	10.307
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	114.8

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	621.517	-	506.705
	=	114.8

Corcept Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Corcept Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Corcept Therapeutics (Corcept Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corcept Therapeutics Inc (NAS:CORT) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

HTD:Germany

Address

149 Commonwealth Drive, Menlo Park, CA, USA, 94025

Website

https://www.corcept.com

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.

Executives

Swisher Daniel N Jr	director	C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
William Guyer	officer: Chief Development Officer	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Gary Charles Robb	officer: CHIEF FINANCIAL OFFICER	C/O 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph Douglas Lyon	officer: Chief Accounting Officer	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Sean Maduck	officer: See Remarks	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
David L Mahoney	director	SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014
Hazel Hunt	officer: Chief Scientific Officer	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph K Belanoff	director, officer: CHIEF EXECUTIVE OFFICER	149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Baker G Leonard Jr	director, 10 percent owner	755 PAGE MILL ROAD, SUITE A-200, PALO ALTO CA 94304-1005
Joshua M. Murray	director	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Atabak Mokari	officer: Chief Financial Officer	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Gillian Cannon	director	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Gregg H Alton	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Kimberly Park	director	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Andreas Grauer	officer: Chief Medical Officer	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025